Medications - FOI Response Register

FoI Number
2023-475
Subject
Medications
Date Received
07/11/2023
Request and Response

Please note some NHS Shetland patients on these treatments are treated by NHS Grampian at the Aberdeen Royal Infirmary. An FOI request to NHS Grampian can be submitted at the following address: gram.foi@nhs.scot

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare. 

Patients with acute myeloid leukaemia (AML)

  1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
  • Azacitidine monotherapy
  • Low dose cytarabine (LoDAC) monotherapy
  • Venetoclax + azacitidine
  • Venetoclax + LoDAC
  • Ivosidenib
  • Intensive chemotherapy-based regimen
  • Other

Nil for all

  1. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
  • Azacitidine monotherapy

Nil

  • Low dose cytarabine (LoDAC) monotherapy

Nil

  • Venetoclax + azacitidine

Nil

  • Venetoclax + LoDAC

Nil

  • Ivosidenib

Nil

  • Intensive chemotherapy-based regimen

<5

NHS Shetland considers that providing more detail carries a high risk of identifying individuals. As such, and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

  • Other

Nil

Note: this should only include patients who have started first-line treatment during the 6-month window.

  1. Of the patients with AML treated with venetoclax + azacitidine in the last 6 months, how many received treatment in line with Scottish Medicines Consortium guidance?

N/A

Patients with chronic lymphocytic leukaemia (CLL)

  1. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window.

Nil

  1. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window.

Nil